Company Overview and News
Blaze International Limited’s (ASX:BLZ) shares have gained circa 30% in response to the company’s anticipated acquisition of Everest Minerals Pty Ltd.
Blaze International (ASX:BLZ) is positioned for a refreshed start to the New Year, as the company prepares to reveal details of a new project acquisition.
Blaze International Limited (ASX:BLZ) has acquired an exploration licence in the Murchison District of Western Australia that is prospective for gold and base metals.
Blaze International (ASX:BLZ) has been granted a trading halt by the ASX, pending an update on the status of one of its projects.
Cadence Minerals Plc (AIM/NEX: KDNC; OTC: KDNCY) is pleased to report that Macarthur Minerals ("Macarthur" or the "Company") in which Cadence currently owns a 16.3% shareholding, has announced that it has entered into an agreement to acquire the Marble Bar Lithium Project and Pippingarra Lithium Tantalite Project in the Pilbara region of Western Australia ("Projects") through a 50:50 joint venture with Southern Hemisphere Mining Ltd (ASX: SUH)("SUH").
Recently the company started a reverse circulation program at the Marble Bar Lithium Project, located west of the Pilgangoora Lithium Project in Western Australia.
Blaze International Ltd (ASX:BLZ) has entered into an option agreement to acquire the Marble Bar Lithium Project in the East Pilbara region of Western Australia. Blaze will join Pilbara Minerals Ltd (ASX:PLS) and Altura Mining Ltd (ASX: AJM) in a region which is becoming a hub for lithium activity, following the discovery of world-class pegmatite deposits. The Marble Bar Lithium Project consists of four exploration licence applications covering 370 square kilometres.
Blaze International Ltd (ASX:BLZ) has been granted a trading halt by the ASX, pending details on a lithium acquisition. The halt will remain in place until the opening of trade on Tuesday 2nd August 2016, or earlier if an announcement is made to the market.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...